| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Tock is a comprehensive platform built to fundamentally change the way restaurants think about and run their business. This includes a robust reservation, guest, and table management system for restaurants of all sizes across the globe.
Proteogenomics Research Institute for Systems Medicine (PRISM) is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hello Phoenix is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PDI Inc. is a provider of contract sales teams to pharmaceutical companies, offering a range of sales support services.